Lv1
100 积分 2023-10-15 加入
Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system
10天前
已完结
Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System
10天前
已完结
Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review
1个月前
已完结
Cryptococcal pneumonia in a patient with rheumatoid arthritis treated with baricitinib
1个月前
已完结
Pneumocystis jirovecii Pneumonia Complicating Use of Upadacitinib in a Patient With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Case Report
1个月前
已完结
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
1个月前
已完结
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
1个月前
已完结
A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
1个月前
已完结
Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis
1个月前
已完结
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
1个月前
已完结
皖公网安备34019202002308
